Champions Oncology (CSBR) Stock Forecast: StockMap's 2-Week Call

CSBR stock forecast: StockMap's model makes no two-week call on Champions Oncology after the Nov 13 close: its evidence is split, 3 reasons for and 12 against. Right in 2 of 3 two-week windows on CSBR since Sep 24; by chance, a call on the same dates was right 51% of the time.

Champions Oncology last closed at $4.71, +1.29% on the session.

Against the IVW growth benchmark the position is +2.20% over the forecast window.

Champions Oncology's market cap is $65.56M as of November 13, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).

Where CSBR sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

27 daily calls for CSBR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Champions Oncology in the 24th percentile on return on equity, where 100 is best.

Champions Oncology is classified under Health Care / Life Sciences Tools & Services.

StockMap tracks Champions Oncology as the 40th largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 25 Neutral, 13 Moderate Outperform, 3 Moderate Underperform and 1 Strong Underperform.

On that composite Champions Oncology ranks 38th of 42 in the group, against a group median of +0.13.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Champions Oncology (CSBR) — StockMap 2-week forecast & tracked accuracy